Cargando…
The clinical pharmacology of depressive states
Antidepressants have good efficacy in the treatment of mood disorders, with effect sizes that have consistently been found to be greater than those of placebo. The more recent antidepressants do not have better efficacy than the compounds discovered 40 to 50 years ago, but they do have a more favora...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181671/ https://www.ncbi.nlm.nih.gov/pubmed/22034133 |
_version_ | 1782212786116362240 |
---|---|
author | Schulz, Pierre Macher, Jean-Paul |
author_facet | Schulz, Pierre Macher, Jean-Paul |
author_sort | Schulz, Pierre |
collection | PubMed |
description | Antidepressants have good efficacy in the treatment of mood disorders, with effect sizes that have consistently been found to be greater than those of placebo. The more recent antidepressants do not have better efficacy than the compounds discovered 40 to 50 years ago, but they do have a more favorable configuration of side effects, leading to fewer dropouts. This favorable situation has made it possible to prescribe the newer antidepressants in less severe depression and in several anxiety disorders, with considerable benefit to patients. During the last decades, research into the pathophysiology of mood and anxiety disorders has provided much information on the brain circuitry, neurohormones, and neurotransmitters involved in these disorders. In parallel, biological and behavioral work on antidepressants, using animal models and new biochemical techniques, has led to a broader understanding of the mode of action of these drugs. Despite this impressive list of discoveries, much research remains to be done on the clinical, psychological, neuropsychological, physiological, and neurochemical aspects, before we can obtain a coherent description of the pathophysiological mechanisms of depression and its treatment. This will lead to a better ability to predict the quality of drug response and, therefore, to the individualization of treatment. |
format | Online Article Text |
id | pubmed-3181671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-31816712011-10-27 The clinical pharmacology of depressive states Schulz, Pierre Macher, Jean-Paul Dialogues Clin Neurosci Pharmacological Aspects Antidepressants have good efficacy in the treatment of mood disorders, with effect sizes that have consistently been found to be greater than those of placebo. The more recent antidepressants do not have better efficacy than the compounds discovered 40 to 50 years ago, but they do have a more favorable configuration of side effects, leading to fewer dropouts. This favorable situation has made it possible to prescribe the newer antidepressants in less severe depression and in several anxiety disorders, with considerable benefit to patients. During the last decades, research into the pathophysiology of mood and anxiety disorders has provided much information on the brain circuitry, neurohormones, and neurotransmitters involved in these disorders. In parallel, biological and behavioral work on antidepressants, using animal models and new biochemical techniques, has led to a broader understanding of the mode of action of these drugs. Despite this impressive list of discoveries, much research remains to be done on the clinical, psychological, neuropsychological, physiological, and neurochemical aspects, before we can obtain a coherent description of the pathophysiological mechanisms of depression and its treatment. This will lead to a better ability to predict the quality of drug response and, therefore, to the individualization of treatment. Les Laboratoires Servier 2002-03 /pmc/articles/PMC3181671/ /pubmed/22034133 Text en Copyright: © 2002 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pharmacological Aspects Schulz, Pierre Macher, Jean-Paul The clinical pharmacology of depressive states |
title | The clinical pharmacology of depressive states
|
title_full | The clinical pharmacology of depressive states
|
title_fullStr | The clinical pharmacology of depressive states
|
title_full_unstemmed | The clinical pharmacology of depressive states
|
title_short | The clinical pharmacology of depressive states
|
title_sort | clinical pharmacology of depressive states |
topic | Pharmacological Aspects |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181671/ https://www.ncbi.nlm.nih.gov/pubmed/22034133 |
work_keys_str_mv | AT schulzpierre theclinicalpharmacologyofdepressivestates AT macherjeanpaul theclinicalpharmacologyofdepressivestates AT schulzpierre clinicalpharmacologyofdepressivestates AT macherjeanpaul clinicalpharmacologyofdepressivestates |